AN2 Therapeutics
AN2 Therapeutics

Financials • AN2 Therapeutics

ANTX

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
0
-22
-12
0%
L
-47
L
-59
-
-21
0
79
-21
0
0
-
-
12/2022
0
-42
-12
0%
L
95
L
-96
-
-38
0
70
-38
-0
0
-
-
12/2023
0
-70
-12
0%
L
125
L
-107
-
-62
0
85
-62
0
0
-
-
12/2024
0
-57
-12
0%
L
82
L
-84
-
-58
0
0
-58
0
0
-
-
12/2025
0
-38
-12
0%
L
53
L
-58
-
-36
0
0
-36
0
0
-
-

To see all financials—including updated, you must be Premium.